Faculty of Medicine, Department of Cardiology, Gaziantep University, 27310, Gaziantep, Turkey.
Faculty of Medicine, Department of Pharmacology, Medeniyet University, Istanbul, Turkey.
Herz. 2021 Feb;46(1):76-81. doi: 10.1007/s00059-019-04842-w. Epub 2019 Aug 14.
New-generation oral anticoagulants (NOACs) are now preferred as a first-line treatment in the management of atrial fibrillation for prevention of thromboembolic complications. Mean platelet volume (MPV), one of the indicators of increased platelet activity, is also associated with an increased stroke risk in atrial fibrillation patients. The aim of this study was to evaluate changes in MPV, platelet distribution width (PDW) and plateletcrit following use of NOACs. The study included 116 patients with non-valvular atrial fibrillation without previous NOAC use. Complete blood counts, biochemical analyses and echocardiography were performed for all patients. No significant differences were observed in MPV or other platelet indices at 6 months compared to baseline. Our results indicate that MPV and other platelet indices are not affected by NOAC use in non-valvular atrial fibrillation patients.
新型口服抗凝剂(NOACs)目前被推荐作为心房颤动管理中预防血栓栓塞并发症的一线治疗药物。血小板平均体积(MPV)是血小板活性增加的指标之一,也与心房颤动患者的中风风险增加有关。本研究旨在评估使用 NOAC 后 MPV、血小板分布宽度(PDW)和血小板比容的变化。该研究纳入了 116 例无先前使用 NOAC 史的非瓣膜性心房颤动患者。所有患者均进行了全血细胞计数、生化分析和超声心动图检查。与基线相比,6 个月时 MPV 或其他血小板指标无显著差异。我们的结果表明,在非瓣膜性心房颤动患者中,NOAC 使用不会影响 MPV 和其他血小板指标。